<DOC>
	<DOCNO>NCT00444353</DOCNO>
	<brief_summary>This study undertaken : - evaluate degree correction attainable DL6049 ( injectable poly-L-lactic acid ) compare commercially available CosmoPlast™ Collagen Implant treatment dermal nasolabial fold wrinkle 13 month follow last application study treatment . - Document type incidence adverse event report DL6049 ( injectable poly-L-lactic acid ) compare CosmoPlast™ Collagen Implant . Long term adverse event assess additional 12 month follow discharge main study subject treat DL6049 .</brief_summary>
	<brief_title>DL6049 Versus Cosmoplast Treatment Nasolabial Fold Wrinkles , Long Term Follow-up</brief_title>
	<detailed_description />
	<criteria>Subjects must sign statement IC HIPAA authorization . In addition subject must provide separate release use photographs publication ; subject right refuse photo release without jeopardize ability participate study . Subjects must 1875 yr age , race sex Female subject must postmenopausal least 1 yr hysterectomy ; tubal ligation ; childbearing potential , must agree use approve method birth control throughout study ( i.e , oral/systemic contraceptive , IUD , spermicide combination barrier method contraception ) . Subjects seek augmentation therapy bilateral correction nasolabial fold . Subjects must score great equal 2 less equal 4 photonumeric wrinkle assessment scale ( assess blind evaluator ) leave right nasolabial fold Visit 1 . Subjects personal history allergic/anaphylactic reaction include hypersensitivity local anesthetic ( e.g. , lidocaine , etc . ) , bovine collagen , latex , silicone , carmellose , mannitol . Subjects know history keloid bleed disorder . Subjects active inflammatory process area treat ( skin eruption cyst , pimple , rash , cancerous/precancerous lesion , active skin disease ) . Subjects active hepatitis within past year . Subjects pregnant ( confirmation pregnancy test ) , plan become pregnant within study timeframe , nursing . Subjects plan undergo major facial surgery ( e.g. , rhinoplasty without implant , facelift , congenital defect repair , etc . course study . Subjects clinically important disease judge investigator within 3 month study ( e.g. , significant lab abnormality , myocardial infarct , stroke , cancer , connective tissue disease , etc . ) include subject medical condition might require use immunosuppressive medication trial ( e.g. , severe asthma , rheumatoid arthritis , etc. ) . Subjects use exclusionary medications/treatments . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2008</verification_date>
</DOC>